Hospital
Woman's Hospital Foundation
Woman's Hospital Foundation was paid $28.51M by Medicaid between Jan 2018 and Dec 2024, across 169 billing codes. Its largest line is 99284, emergency room visit (serious) — 10% of everything it billed.
33Billing provider infoWOMAN'S HOSPITAL FOUNDATION
BATON ROUGE, LA 70817
BATON ROUGE, LA 70817
33aNPI1912943184assigned 06/22/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$28.51M
24GClaims649,920
24DCodes billed169
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#15 of 96
Median peer was paid$5.17M
This provider vs. median5.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 64,564 | $2.23M | |
| 2019 | 67,709 | $2.25M | |
| 2020 | 77,518 | $3.12M | |
| 2021 | 118,679 | $5.38M | |
| 2022 | 112,220 | $5.29M | |
| 2023 | 102,099 | $5.11M | |
| 2024incomplete | 107,131 | $5.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 8,887 | 8,026 | $2.98M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.9% | 12,005 | 10,637 | $2.54M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 7.5% | 15,994 | 13,437 | $2.15M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.9% | 15,867 | 14,380 | $1.96M |
| 76819 | Fetal biophysical profile; without non-stress testing | 6.8% | 11,099 | 9,184 | $1.95M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.6% | 57,203 | 50,465 | $1.88M |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 6.2% | 6,680 | 5,799 | $1.78M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.4% | 39,336 | 35,596 | $1.26M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.4% | 39,361 | 35,532 | $1.26M |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 3.2% | 8,137 | 6,605 | $900K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 3.0% | 28,469 | 25,141 | $869K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 2.5% | 5,131 | 4,347 | $708K |
157 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.2% | 21,918 | $629K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 2.1% | 3,374 | $592K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | 2.0% | 934 | $564K |
| 59025 | Fetal non-stress test | 1.9% | 4,009 | $529K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.8% | 24,571 | $515K |
| 80081 | 1.3% | 5,569 | $374K | |
| 19318 | 1.2% | 704 | $346K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.0% | 14,531 | $299K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 48,244 | $299K |
| 76830 | Ultrasound, transvaginal | <1% | 1,299 | $259K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 8,879 | $258K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 438 | $248K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 7,310 | $221K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,432 | $215K |
| 81025 | <1% | 30,064 | $189K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,454 | $146K |
| 80306 | <1% | 9,468 | $141K | |
| 76857 | <1% | 1,263 | $138K | |
| 86703 | <1% | 11,731 | $123K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 17,992 | $118K |
| 87653 | <1% | 3,417 | $116K | |
| 99285 | Emergency room visit (most serious) | <1% | 236 | $115K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 826 | $103K |
| 80053 | Comprehensive metabolic panel | <1% | 12,131 | $98K |
| 84702 | <1% | 7,558 | $97K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,473 | $86K |
| 77066 | Tomosynthesis, mammo | <1% | 825 | $77K |
| 87660 | <1% | 4,834 | $77K | |
| 87480 | <1% | 4,580 | $74K | |
| 87510 | <1% | 4,582 | $73K | |
| 76642 | <1% | 522 | $69K | |
| 86592 | <1% | 16,202 | $66K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,035 | $64K |
| 81000 | <1% | 20,702 | $62K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,069 | $58K |
| 80055 | <1% | 2,612 | $51K | |
| 90715 | <1% | 1,911 | $50K | |
| 76801 | <1% | 311 | $46K | |
| T2101 | Human breast milk processing, storage and distribution only | <1% | 2,287 | $39K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,209 | $38K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 401 | $35K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,048 | $33K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,421 | $33K |
| 86803 | <1% | 2,233 | $26K | |
| 82950 | <1% | 5,834 | $26K | |
| 87210 | <1% | 6,666 | $25K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 507 | $25K |
| 85660 | <1% | 4,800 | $23K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,848 | $23K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 451 | $21K |
| 81002 | <1% | 7,504 | $18K | |
| 86300 | <1% | 923 | $16K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,245 | $14K |
| 82378 | <1% | 880 | $14K | |
| 76820 | <1% | 118 | $14K | |
| 82951 | <1% | 1,065 | $13K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 856 | $13K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 219 | $12K |
| 87340 | <1% | 1,104 | $11K | |
| 87070 | <1% | 1,500 | $11K | |
| 90686 | <1% | 706 | $10K | |
| 77062 | <1% | 563 | $10K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,959 | $9K |
| 82947 | <1% | 1,928 | $8K | |
| 90651 | <1% | 36 | $7K | |
| 83615 | <1% | 1,336 | $7K | |
| J3490 | Unclassified drugs | <1% | 3,398 | $6K |
| 87205 | <1% | 1,613 | $6K | |
| 82677 | <1% | 265 | $6K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 14 | $6K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 42 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,158 | $6K |
| 81001 | <1% | 2,293 | $6K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 56 | $5K |
| 81003 | <1% | 4,628 | $5K | |
| G0378 | Hospital observation service, per hour | <1% | 16 | $5K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 330 | $5K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 48 | $4K |
| 82105 | <1% | 278 | $4K | |
| 86336 | <1% | 278 | $4K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 234 | $4K |
| 85044 | <1% | 980 | $4K | |
| 96417 | <1% | 51 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 158 | $3K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 162 | $3K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 261 | $3K |
| 80061 | Lipid panel | <1% | 249 | $3K |
| 86850 | <1% | 1,512 | $3K | |
| 82962 | <1% | 675 | $2K | |
| 86780 | <1% | 234 | $2K | |
| V5266 | Battery for use in hearing device | <1% | 328 | $2K |
| 86704 | <1% | 193 | $2K | |
| 84460 | <1% | 484 | $2K | |
| 84450 | <1% | 484 | $2K | |
| 84439 | <1% | 230 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,134 | $2K |
| 82565 | <1% | 431 | $2K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 26 | $2K |
| 86706 | <1% | 167 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,466 | $2K |
| 84550 | <1% | 470 | $2K | |
| 84146 | <1% | 92 | $2K | |
| 86900 | <1% | 1,743 | $2K | |
| 86901 | <1% | 1,684 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 589 | $1K |
| 99385 | <1% | 101 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 456 | $1K |
| 84520 | <1% | 446 | $1K | |
| 81005 | <1% | 797 | $1K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 24 | $1K |
| 82570 | <1% | 330 | $1K | |
| 71045 | Radiologic examination, chest; single view | <1% | 12 | $1K |
| 90656 | <1% | 122 | $1K | |
| 94762 | <1% | 191 | $991.65 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 26 | $857.90 |
| 84156 | <1% | 346 | $803.65 | |
| 00402 | <1% | 396 | $780.84 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,297 | $747.17 |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 23 | $521.97 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 13 | $473.05 |
| 85027 | <1% | 375 | $463.29 | |
| 88142 | <1% | 58 | $402.87 | |
| 86304 | <1% | 34 | $378.74 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13 | $335.09 |
| 0002A | <1% | 17 | $293.37 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 17 | $259.72 |
| 83690 | <1% | 44 | $256.29 | |
| 86705 | <1% | 16 | $213.15 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 48 | $178.08 |
| 84134 | <1% | 27 | $166.32 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 152 | $164.87 |
| 0001A | <1% | 18 | $160.00 | |
| 82607 | <1% | 19 | $146.40 | |
| 82746 | <1% | 19 | $142.76 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 62 | $141.45 |
| 82952 | <1% | 37 | $137.20 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 56 | $114.92 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 150 | $114.40 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 779 | $78.09 |
| 82248 | <1% | 13 | $58.08 | |
| 82247 | <1% | 13 | $58.08 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 628 | $53.85 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 15 | $49.38 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 184 | $47.46 |
| A6223 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 557 | $40.61 |
| A4600 | Sleeve for intermittent limb compression device, replacement only, each | <1% | 79 | $32.81 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 39 | $26.62 |
| A9150 | Non-prescription drugs | <1% | 135 | $24.71 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 136 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 13 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 16 | $0.00 |
| 91300 | 0% | 37 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 136 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 49 | $0.00 |
| 94770 | 0% | 26 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 28 | $0.00 |
| 00400 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFONTENOT, TERI (CEO & PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Woman's Maternal Fetal Medicine | Baton Rouge, LA | $2.21M |
| Woman's Assessment Center Physicians | Baton Rouge, LA | $2.18M |
| Womans Outpatient Clinic Providers | Baton Rouge, LA | $1.04M |
| Womans Physician Group | Gonzales, LA | $184K |
| Woman's Surgical Specialty Group | Baton Rouge, LA | $158K |
| Woman's Specialty Clinic | Baton Rouge, LA | $116K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.